Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics (NASDAQ: TVTX) announced on December 10, 2025 that its Compensation Committee granted inducement equity awards to five new employees totaling 20,300 restricted stock units (RSUs).
The RSUs were granted outside the 2018 Equity Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years with 25% vesting each anniversary, subject to continued service through each vesting date.
Travere Therapeutics (NASDAQ: TVTX) announced that on November 10, 2025 its Compensation Committee granted inducement restricted stock units to three new employees totaling 25,700 RSUs. The grants were made outside the company’s 2018 Equity Incentive Plan but subject to its terms as permitted under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continued service through each vesting date.
Travere Therapeutics (Nasdaq: TVTX) presented late-breaking Phase 3 DUPLEX data at ASN Kidney Week 2025 (Nov 6-9). The analyses show FILSPARI (sparsentan) patients were more likely to reach urine protein-to-creatinine ratio (UPCR) below 0.7 g/g versus maximum labeled dose irbesartan (37.5% vs 21.4%, RR 1.8).
At week 108, rates were 19% vs 11.2% (RR 1.7). DUPLEX-aligned RaDaR modeling linked achieving UPCR0.7 g/g at 24 months to markedly lower five-year kidney-failure risk (HR 0.14); applying a 26% relative UPCR reduction for FILSPARI translated to a modeled (HR 0.76).
Travere Therapeutics (NASDAQ: TVTX) said company management will participate in multiple investor conferences in November–December 2025, including Guggenheim Healthcare (Nov 11, 2025 at 9:00 a.m. ET), Stifel Healthcare (Nov 12, 2025), TD Cowen Immunology & Inflammation (Nov 13, 2025 at 4:00 p.m. ET), Jefferies Global Healthcare (Nov 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET), Evercore Healthcare (Dec 2, 2025 at 10:50 a.m. ET) and Piper Sandler Healthcare (Dec 3, 2025).
Live webcasts of presentations will be available on the company investor page at ir.travere.com/events-and-presentations, with replays accessible for up to 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) reported 3Q 2025 total revenue of $164.9 million, which included a $40.0 million market access milestone and license revenue. The company reported a $25.7 million net income for 3Q 2025 (or $0.29 per basic share) versus a net loss in the year-ago quarter and held $254.5 million in cash, cash equivalents and marketable securities as of Sept 30, 2025. FILSPARI commercial momentum continued: the release cites 155% year-over-year U.S. growth and program updates ahead of a PDUFA target action date of Jan 13, 2026 for FSGS. The company also repaid roughly $68.9 million of 2025 convertible notes and reported progress on pegtibatinase development and global partnerships.
Travere Therapeutics (NASDAQ: TVTX) will report third quarter 2025 financial results on Thursday, October 30, 2025 after market close.
The company will host a conference call and webcast to discuss results and provide a business update at 4:30 p.m. ET. Webcast and dial-in details are available on Travere's Investor Events page, and an archived recording will be available for 30 days after the live event.
Travere Therapeutics (Nasdaq: TVTX) will present 11 abstracts at ASN Kidney Week 2025 in Houston, Nov 6–9, 2025.
Key highlights include a late-breaking DUPLEX analysis showing more FILSPARI (sparsentan)-treated patients reached proteinuria <0.7 g/g versus maximum labeled irbesartan, and that reaching this threshold correlated with reduced kidney failure risk regardless of treatment arm. Additional DUPLEX data show rapid, sustained proteinuria reductions in children and in patients with COL4A3-5 variants. SPARTAN presentations report anti-inflammatory and anti-fibrotic biomarker effects in RASI-naïve IgAN patients and favorable cardiovascular safety signals, plus real-world evidence and PROTECT analyses of consistent, superior proteinuria reduction with FILSPARI.
Travere Therapeutics (NASDAQ: TVTX) announced on October 10, 2025 that its Compensation Committee approved inducement equity grants covering an aggregate of 228,600 shares to 43 new employees.
The awards comprise inducement stock options for 50,000 shares and inducement restricted stock units (RSUs) for 178,600 shares, granted outside the 2018 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $25.16 (closing price on the grant date), are non-qualified, carry a 10-year term and vest over four years (25% after one year, then monthly over 36 months). The RSUs vest over four years with 25% vesting on each anniversary. All awards vest subject to continued service.
CSL Vifor (OTC:CSLLY) and Travere Therapeutics announced recognition of updated KDIGO clinical practice guidelines for IgA Nephropathy (IgAN) treatment. The 2025 guidelines highlight their drug FILSPARI® (sparsentan) as a potential first-line treatment approach, being the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA) with proven efficacy compared to optimized RASi in clinical trials.
The updated guidelines establish key treatment goals including proteinuria remission and slowing eGFR decline. FILSPARI, which is approved in the U.S. and Europe, has been launched in multiple European countries including Germany, Austria, Switzerland, Luxembourg, and the UK. The guidelines were presented at the International Symposium of IgA Nephropathy in September 2025.
Travere Therapeutics (NASDAQ: TVTX) announced the granting of inducement equity awards to 20 new employees. The Compensation Committee approved restricted stock units (RSUs) covering 69,300 shares of common stock on September 10, 2025.
The RSUs were granted outside of the company's 2018 Equity Incentive Plan but are subject to its terms. These grants, made under Nasdaq Listing Rule 5635(c)(4), will vest over four years with 25% vesting annually, contingent on continued employment.